StockData

Dianthus Therapeutics, Inc. (DNTH) stock

DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$83.98−3.00 (-3.45%)

Close on Nov 18, 2026Market cap $4.70BP/E –Yield 0.00%

Dianthus Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Dianthus Therapeutics's free cash flow for the twelve months ending Jun 30, 2023 was -$7.89M. For fiscal 2022 it was -$29.38M. The highest annual figure on record is -$6.67M in fiscal 2016.

Annual free cash flow

PeriodPeriod endValueChange
FY2022Dec 31, 2022-$29.38M–
FY2021Dec 31, 2021-$60.80M–
FY2020Dec 31, 2020-$64.42M–
FY2019Dec 31, 2019-$60.16M–
FY2018Dec 31, 2018-$49.56M–
FY2017Dec 31, 2017-$24.46M–
FY2016Dec 31, 2016-$6.67M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2023Jun 30, 2023-$4.73M–
Q1 FY2023Mar 31, 2023-$10.53M–
Q4 FY2022Dec 31, 2022-$8.85M–
Q3 FY2022Sep 30, 2022$16.22M–
Q2 FY2022Jun 30, 2022-$16.98M–
Q1 FY2022Mar 31, 2022-$19.77M–
Q4 FY2021Dec 31, 2021-$15.71M–
Q3 FY2021Sep 30, 2021-$15.20M–
Q2 FY2021Jun 30, 2021-$13.11M–
Q1 FY2021Mar 31, 2021-$16.78M–
Q4 FY2020Dec 31, 2020-$13.95M–
Q3 FY2020Sep 30, 2020-$14.45M–
Q2 FY2020Jun 30, 2020-$19.24M–
Q1 FY2020Mar 31, 2020-$16.79M–
Q4 FY2019Dec 31, 2019-$15.78M–
Q3 FY2019Sep 30, 2019-$12.04M–
Q2 FY2019Jun 30, 2019-$16.16M–
Q1 FY2019Mar 31, 2019-$16.19M–
Q4 FY2018Dec 31, 2018-$16.98M–
Q3 FY2018Sep 30, 2018-$13.02M–
Q2 FY2018Jun 30, 2018-$9.79M–
Q1 FY2018Mar 31, 2018-$9.77M–
Q4 FY2017Dec 31, 2017-$8.55M–
Q3 FY2017Sep 30, 2017-$5.83M–

More Dianthus Therapeutics figures

See a number that looks wrong?